XML 64 R18.htm IDEA: XBRL DOCUMENT
v3.21.1

Share-Based Payments | 12 Months Ended
--- | ---
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Share-Based Payments | 10. Share-Based Payments In 2016, the Company adopted the 2016 Stock Plan. On July 8, 2020, the Company’s stockholders approved the 2020 Stock Option and Incentive Plan (the “2020 Stock Plan”), which became effective on the date immediately prior to the effectiveness of the Company’s registration statement on Form S-1 for its IPO. The 2020 Stock Plan provides for the issuance of up to 8,376,080 of share-based awards. Subsequent to July 20, 2020, no further awards will be made under the 2016 Stock Plan and all future equity-based awards will be granted under the 2020 Stock Plan. To the extent outstanding options granted under the 2016 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2016 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Plan. All of the Company’s employees, officers, directors and consultants are eligible to be granted options, restricted stock units and other stock-based awards under the terms of the 2020 Stock Plan. There were 8,026,772 share-based awards available for grant at December 31, 2020. The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December 31, 2020:
|  | Number of Stock Options |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Term (years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2019 |  |  | 5,306,176 |  |  | $ | 4.62 |  |  |  | 8.99 |  |  | $ | 3,214 |
Granted |  |  | 2,898,663 |  |  |  | 10.90 |  |  |  |  |  |  |  |  |
Exercised |  |  | (297,000 | ) |  |  | 4.09 |  |  |  |  |  |  |  |  |
Cancelled |  |  | (210,781 | ) |  |  | 4.91 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 7,697,058 |  |  | $ | 6.99 |  |  |  | 8.50 |  |  | $ | 266,050 |
Vested at December 31, 2020 |  |  | 2,148,119 |  |  | $ | 4.49 |  |  |  | 7.90 |  |  | $ | 79,625 |
Non-vested at December 31, 2020 |  |  | 5,548,939 |  |  | $ | 7.96 |  |  |  | 8.74 |  |  | $ | 186,425 |
In the first quarter of 2020, the Company’s board of directors approved the issuance of options with performance-based vesting conditions to purchase 1,960,547 shares of common stock. The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company’s board of directors. Accordingly, the Company applied variable accounting for these awards until the board of directors approved the commencement of vesting for the options. The service inception date preceded the grant date for these awards as the awards were authorized prior to the grant date, the recipients were providing service prior to the grant date and there were performance conditions that, if not met by the accounting grant date, would have resulted in the forfeiture of the award. The stock-based compensation expense for the options was determined based on the fair value of the awards on the accounting grant date. The Company’s board of directors, in its discretion, determined that a portion of the performance conditions were achieved during the second quarter of 2020 and that the remaining portion of the performance conditions were achieved during the fourth quarter of 2020. The grant dates for all performance-based awards was therefore known as of December 31, 2020, and all performance conditions have been resolved. The Company recognized stock-based compensation expense associated with the awards with performance-based vesting conditions in the amount of $25,527 in the statement of operations for the year ended December 31, 2020. Expense for these awards is recognized using an accelerated attribution model, over the four-year vesting term, commencing upon grant date. The Company estimated the fair value of its stock options using the following assumptions:
|  | Year Ended December 31, |
|  | 2020 |  |  | 2019 |
Risk-free interest rate |  | 0.4 - 1.8% |  |  | 1.5 – 2.5% |
Expected term (in years) |  |  | 6.3 |  |  |  | 6.3 |
Expected volatility |  | 73.5 - 77.6% |  |  | 72.8 – 73.47% |
Expected dividend yield |  |  | 0 | % |  |  | 0 | %
The weighted average grant date fair value of stock options granted during the years ended December 31, 2020 and 2019 was $30.14 per share and $3.34 per share, respectively. Stock-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss is as follows:
|  | Year Ended December 31, |
|  | 2020 |  |  | 2019 |
Research and development expenses |  | $ | 14,691 |  |  | $ | 2,687 |
General and administrative expenses |  |  | 17,269 |  |  |  | 1,769 |
|  | $ | 31,960 |  |  | $ | 4,456 |
As of December 31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $69,948, which is expected to be recognized over a weighted average period of 2.61 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration